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Abstract
Background: Genome-scale pooled CRISPR screens are powerful tools for identifying genetic dependencies across
varied cellular processes. The vast majority of CRISPR screens reported to date have focused exclusively on the
perturbation of protein-coding gene function. However, protein-coding genes comprise < 2% of the sequence
space in the human genome leaving a substantial portion of the genome uninterrogated. Noncoding regions of
the genome harbor important regulatory elements (e.g. promoters, enhancers, silencers) that influence cellular
processes but high-throughput methods for evaluating their essentiality have yet to be established.
Results: Here, we describe a CRISPR-based screening approach that facilitates the functional profiling of thousands
of noncoding regulatory elements in parallel. We selected the tumor suppressor p53 as a model system and
designed a pooled CRISPR library targeting thousands of p53 binding sites throughout the genome. Following
transduction into dCas9-KRAB-expressing cells we identified several regulatory elements that influence cell
proliferation. Moreover, we uncovered multiple elements that are required for the p53-mediated DNA damage
response. Surprisingly, many of these elements are located deep within intergenic regions of the genome that have
no prior functional annotations.
Conclusions: This work diversifies the applications for pooled CRISPR screens and provides a framework for future
functional studies focused on noncoding regulatory elements.
Keywords: CRISPR, CRISPR screen, Regulatory element, Enhancer, p53

Background
The ability to modify genomic DNA using the CRISPR/
Cas9 system has rapidly transformed the field of functional genomics [1–4]. In addition to its applications in
high fidelity genome engineering, the CRISPR/Cas9 system can be readily adapted for use in lentiviral-based
pooled genetic screens [5, 6]. Pooled CRISPR screens
permit the rapid identification of genes involved in a
wide variety of biological processes and have become a
routine experimental approach for dissecting complex
genetic pathways [7, 8]. Although commonly used for
characterizing the impact of gene knockout on cellular
phenotypes, advances in CRISPR-based methods have
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enabled pooled CRISPR screens that profile the consequences of gene activation or gene repression [9–14].
The majority of CRISPR screens reported to date have
focused exclusively on the function of protein-coding
genes. In contrast, relatively few reports have described
pooled screens that interrogate the function of noncoding regulatory elements. Many of the studies that have
utilized pooled screens to characterize regulatory elements have designed dense tiling CRISPR libraries with
genomic target sites that are restricted to sequences immediately adjacent to a gene of interest [15–17]. Isolated
reports have described pooled CRISPR screens that target regulatory elements dispersed throughout the genome. For example, a pooled CRISPR screen targeting
685 p53-bound regions was able to identify a functional
enhancer element upstream of CDKN1A [18]. In
addition, a pooled CRISPR screen targeting 398 AP1bound regions was able to identify an enhancer element
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that regulates FOXF1 expression [19]. While these
studies have provided proof of concept for the application of pooled CRISPR screening in the functional
characterization of regulatory elements, they were
focused on profiling predicted regulatory elements as
opposed to the identification of novel regulatory elements. Furthermore, they were not designed to yield
generalizable insights into screening methodologies. Importantly, the practical considerations for the design and
execution of pooled CRISPR screens that profile the
function of noncoding regulatory elements at genome
scale have yet to be defined.
The tumor suppressor p53 is a master regulator of cell
fate decisions and a central line of defense against genomic instability [20–24]. While traditionally considered
a transcription factor that binds to gene promoters and
regulates gene expression, several recent reports have
found that p53 binds predominantly to putative enhancer elements [25–29]. Multiplexed reporter assays have
further revealed that the majority of genomic sequences
bound by p53 exhibit potent enhancer activity [30, 31].
Moreover, p53 has been shown to modulate chromatin
accessibility at a subset of enhancer elements in response
to DNA damage [30]. While these studies have suggested that enhancer regulation is an important component of the p53 network the functional significance of
p53-bound regulatory elements in the context of cell fate
decisions remains unclear.
Here, we use p53 as a model system to evaluate pooled
CRISPR screening methods for characterizing the function of noncoding regulatory elements. We designed a
pooled CRISPR library targeting p53 binding sites
throughout the genome and profile the functional
significance of these sites in multiple biological contexts.
We demonstrate that pooled CRISPR screens are capable of distinguishing p53-bound regulatory elements
that influence cell proliferation and/or cell cycle arrest
in response to DNA damage. While some of the regulatory elements we identified are well-characterized p53
targets, many are located within intergenic regions of
the genome that lack prior functional annotations. Importantly, orthogonal experimental approaches were able
to confirm the functional significance for several of these
intergenic regulatory elements.
In addition to identifying p53-bound regulatory
elements that influence cell proliferation and/or cell
cycle arrest in response to DNA damage we explore a
variety of practical considerations for the use of pooled
CRISPR screens to profile the function of regulatory elements. Most notably, we perform each of our screens
using both CRISPR interference (CRISPRi) and CRISPR
knockout (CRISPRko) technologies allowing us to directly compare the different screening approaches. Surprisingly, we observed minimal overlap in screening

Page 2 of 15

results across technologies and demonstrate that screens
performed using CRISPRi more closely recapitulate
known biology. Altogether, our findings provide valuable
insight into the design of CRISPR-based screening
approaches for profiling the function of noncoding regulatory elements.

Results
CRISPR-mediated knockout of wildtype p53 increases cell
proliferation in a subset of cancer cell lines

In order to identify an ideal cell-based model system
to profile p53 function we took advantage of publicly
available data generated through Project Achilles [32].
Briefly, Project Achilles utilizes genome-scale CRISPR
knockout screens to identify genetic dependencies
across a large compendium of cancer cell lines. The
effect of knocking out each individual gene during a
CRISPR screen is reported as a gene-level ‘Enrichment Score’. These scores are calculated based on
changes in the relative abundance of cells harboring
sgRNAs targeting each respective gene over the
course of a screen. Therefore, these ‘Enrichment
Scores’ serve as a proxy for the impact of gene
knockout on cell proliferation. We profiled p53 ‘Enrichment Scores’ across more than 350 cancer cell
lines and found that p53 knockout had no effect on
cell proliferation for many of the cell lines screened
in Project Achilles. However, we were able to identify
a subset of cell lines in which p53 knockout conferred a proliferative advantage (Fig. 1a).
To identify molecular features associated with cell
lines in which p53 knockout resulted in a proliferative
advantage we intersected p53 ‘Enrichment Scores’ with
data from the IARC (International Agency for Research
on Cancer) TP53 database [33]. The IARC TP53
database is a curated resource for the mutation status of
p53, along with several other known tumor suppressors
and oncogenes, in human cell lines. Consistent with
known p53 biology, we found that the proliferative advantage of p53 knockout was specific to cell lines harboring wildtype p53 (Fig. 1a, Additional file 1: Figure S1,
Additional file 6: Table S1). In contrast, p53 knockout in
cell lines containing mutations in the p53 gene, loss of
p53 expression mutations, or p53 deletions had no significant impact on cell proliferation (Fig. 1a, Additional
file 1: Figure S1, Additional file 6: Table S1). Collectively,
these results indicate that cell proliferation can be used
as a phenotype to screen p53 function in cell lines harboring wildtype copies of the gene.
To select a cell line for screening p53 function we
first narrowed the list of cancer cell lines screened
through Project Achilles down to those harboring
wildtype p53. We then used data from the IARC
TP53 database to further restrict this list to cell lines
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Fig. 1 p53 knockout increases cell proliferation. a Distribution of p53 enrichment scores from pooled CRISPR knockout screens in 350 cancer cell
lines. b p53 enrichment scores in a selected subset of cancer cell lines containing wildtype p53. c Western blot analysis of Cas9 expression in
769P cells. d Comparison of log2 fold changes (relative to pDNA) for all sgRNAs in CRISPR library between replicates. e Visualization of
enrichment/depletion for sgRNAs targeting a selected subset of genes (red) compared to all sgRNAs in CRISPR library (black)

with no documented mutations in other known tumor
suppressors or oncogenes (e.g. PTEN, KRAS, BRAF)
(Additional file 6: Table S1). In total, we identified 8
cell lines that met our stringent criteria (Fig. 1b). The
human renal adenocarcinoma cell line 769P displayed
the highest p53 ‘Enrichment Score’ in the Project
Achilles data and was selected as a model cell line for
all subsequent experiments (Fig. 1b).

Pooled CRISPR screen identifies p53-regulated genes that
influence cell proliferation

To determine if a pooled CRISPR screen would be able
to identify downstream targets of p53 that influence cell
proliferation we designed a proliferation-based CRISPR
screen. We generated a list of 330 genes that have p53
binding sites within 10 kb of their transcription start site
and have been predicted to be directly regulated by p53
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in a previous study [29]. We constructed a CRISPR library containing 4 sgRNAs targeting each gene in this
list as well as 4 sgRNAs targeting p53 (Additional file 7:
Table S2). As controls this CRISPR library included 70
sgRNAs targeting intergenic regions of the human
genome and 70 sgRNAs with no genomic targets
(Additional file 7: Table S2). We refer to this library
throughout this report as our gene-targeting CRISPR
library.
In order to perform CRISPR knockout (CRISPRko)
screens we next generated a 769P-derived cell line expressing Cas9. We stably integrated Cas9 into a population of 769P cells using lentivirus and confirmed Cas9
expression by western blot (Fig. 1c). We then infected
the Cas9-expressing 769P cells with our gene-targeting
library at a multiplicity of infection (MOI) of ~ 0.5 and a
representation of 1000 cells per sgRNA. Library-infected
cells were cultured for 21 days, genomic DNA was isolated, and targeted sequencing was performed to evaluate changes in sgRNA abundance relative to the CRISPR
library pDNA (Additional file 8: Table S3).
To calculate changes in sgRNA abundance over the
course of the screen we utilized MAGeCK, a computational tool for model-based analysis of pooled CRISPR
screens [34]. Analysis with MAGeCK revealed a significant correlation in sgRNA enrichment/depletion across
biological replicates indicating that our screening results
are highly reproducible (Fig. 1d, Additional file 9: Table
S4). Moreover, sgRNAs targeting p53 were among the
most enriched in our screen, confirming the validity of
our approach (Fig. 1e, Additional file 10: Table S5). In
addition to p53 we identified several p53-regulated genes
in which knockout resulted in a significant proliferative
advantage (Fig. 1e, Additional file 10: Table S5). Interestingly, we also uncovered a subset of p53-regulated genes
where knockout lead to a proliferative disadvantage (Fig.
1e, Additional file 10: Table S5). These data demonstrate
that proliferation-based CRISPR screens can be used to
functionally profile downstream events in the p53
pathway.
Pooled CRISPR screen identifies p53-bound regulatory
elements that influence cell proliferation

Having established that CRISPR screens can be used to
profile downstream events in the p53 pathway we next
designed a screening approach to identify regulatory
elements bound by p53 that mediate its influence on cell
proliferation. More specifically, we designed a CRISPR
library to target and inhibit the function of p53-bound
regulatory elements. We used previously reported p53
ChIP-Seq data to identify p53 binding sites throughout
the human genome [29]. We then searched for p53 consensus motifs (CWWG [N]2-12CWWG) located within
each p53 ChIP-Seq peak (Fig. 2a). Once found, we
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designed sgRNAs targeting all PAM-containing sequences located within 16 bp upstream or downstream
of the consensus motif. In total, we designed 11,434
sgRNAs targeting 4930 motifs located within 2036 p53
ChIP-Seq peaks (Fig. 2b, c, d, Additional file 11: Table
S6). While many p53 motifs could only be targeted by a
single sgRNA, the majority of the motifs we identified
were targeted by multiple sgRNAs in our CRISPR library
(Fig. 2d). Likewise, 83% (1703/2036) of the ChIP-Seq
peaks represented in our CRISPR library were targeted
by multiple sgRNAs (Fig. 2c). As controls we also included 500 sgRNAs targeting intergenic regions of the
human genome and 500 sgRNAs with no genomic
targets (Additional file 11: Table S6). We refer to this
library throughout this report as our peak-targeting
CRISPR library.
In order to perform CRISPR interference (CRISPRi)
screens we next generated a 769P-derived cell line expressing a nuclease-dead version of Cas9 fused to the
KRAB repressive domain (dCas9-KRAB). We stably integrated dCas9-KRAB into a population of 769P cells
using lentivirus and confirmed dCas9-KRAB expression
by western blot (Fig. 2e). We then infected the dCas9KRAB-expressing 769P cells with our peak-targeting
library at an MOI of ~ 0.5 and a representation of 1000
cells per sgRNA. Library-infected cells were cultured for
21 days, genomic DNA was isolated, and targeted
sequencing was performed to evaluate changes in
sgRNA abundance relative to the CRISPR library pDNA
(Additional file 12: Table S7).
We again used MAGeCK to calculate changes in sgRNA
abundance during the screen and observed a moderate
correlation in sgRNA enrichment/depletion across
biological replicates (Fig. 2f, Additional file 13: Table S8).
Among the most enriched sgRNAs in the screen were
those targeting a ChIP-Seq peak (Peak 974) located upstream of CDKN1A, a gene that was significantly enriched
in screens performed with the gene-targeting CRISPR
library (Fig. 2g, Additional file 14: Table S9). Surprisingly,
we identified many p53 binding sites in which CRISPRimediated repression resulted in a significant proliferative
disadvantage (Fig. 2g, h). While some of these p53 binding
sites were located proximal to an annotated transcription
start site (TSS), most were located more than 10 kb away
from the nearest TSS (Fig. 2i). Collectively, these data
demonstrate that proliferation-based CRISPRi screens can
be used to functionally profile regulatory elements that
are bound by p53.
To evaluate the ability of CRISPRko technology to
identify functional regulatory elements we performed
screens using our peak-targeting CRISPR library in cells
expressing Cas9 as opposed to dCas9-KRAB. We infected Cas9-expressing 769P cells with our peaktargeting CRISPR library at an MOI of ~ 0.5 and a
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Fig. 2 p53-bound regulatory elements influence cell proliferation. a p53 binding sites as determined by ChIP-Seq (black) and p53 consensus
motifs (grey). b Distribution of distances to nearest annotated transcription start site for all sgRNAs in CRISPR library. c Distribution of number of
sgRNA designs per p53 ChIP-Seq peak. d Distribution of number of sgRNA designs per p53 consensus motif. e Western blot analysis of dCas9KRAB expression in 769P cells. f Comparison of log2 fold changes (relative to pDNA) for all sgRNAs in CRISPR library between replicates. g Volcano
plot comparing significance of sgRNA enrichment/depletion and log2 fold change (relative to pDNA) for all sgRNAs in CRISPR library. h
Visualization of enrichment/depletion for sgRNAs targeting a selected subset of peaks (red) compared to all sgRNAs in CRISPR library (black). i
Comparison of log2 fold change (relative to pDNA) and distance from nearest annotated TSS for all sgRNAs in CRISPR library

representation of 1000 cells per sgRNA, cultured the infected cells for 21 days, isolated genomic DNA, and performed targeted sequencing to evaluate changes in
sgRNA abundance relative to the CRISPR library pDNA
(Additional file 15: Table S10). Analysis with MAGeCK
revealed a moderate correlation in sgRNA enrichment/
depletion across biological replicates indicating that our
screening results are reproducible (Additional file 2:
Figure S2A, Additional file 16: Table S11). Similar to our
findings in dCas9-KRAB-expressing 769P cells we identified many p53 binding sites in which CRISPR-mediated
knockout resulted in a significant proliferative disadvantage (Additional file 2: Figure S2B, Additional file 2:
Figure S2C, Additional file 17: Table S12). Once again,

most of these p53 binding sites were located more than
10 kb away from the nearest TSS (Additional file 2: Figure S2D). Interestingly, we observed minimal overlap in
the sgRNAs that were significantly enriched/depleted
across the CRISPRko and CRISPRi screens. Moreover,
the overall concordance of enrichment/depletion for all
sgRNAs in the peak-targeting CRISPR library was strikingly low (Additional file 2: Figure S2E). In contrast to
our CRISPRi screen results we were unable to associate
any p53 binding sites identified in the CRISPRko screen
with genes that were significantly enriched/depleted in
our gene-targeting CRISPR screen. Based on these data
we focused our validation efforts on p53 binding sites
identified in our CRISPRi screen.

Borys and Younger BMC Genomics

(2020) 21:107

Repression of p53-bound regulatory elements impacts
cell proliferation

Among the sgRNAs that were most depleted in our
peak-targeting CRISPRi screen were those targeting Peak
2319 (Fig. 2h). Peak 2319 is located within the first intron of RAD51C, a gene determined to be essential for
cell proliferation in our gene-targeting CRISPRko screen
(Fig. 3a, Fig. 1e). Peak 2319 contains three p53 motifs,
two of which were targeted by sgRNAs in our peaktargeting CRISPR library (Fig. 3a). We found that
sgRNAs targeting both motifs were significantly depleted
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in our peak-targeting CRISPRi screen (Fig. 3b). We reasoned that the p53 binding sites located within Peak
2319 are components of a downstream regulatory element that modulate RAD51C expression and selected
sgRNAs targeting Peak 2319 and RAD51C for experimental validation.
Also among the most depleted sgRNAs in our peaktargeting CRISPRi screen were those targeting Peak 384
(Fig. 2h). In contrast to the close proximity between
Peak 2319 and RAD51C, Peak 384 is located more than
200 kb away from the nearest annotated protein-coding

Fig. 3 Functional characterization of p53-bound regulatory elements that influence cell proliferation. a Schematic of p53 motifs and sgRNA
targets located in Peak 2319. (ChromHMM track legend: red = active promoter; orange = strong enhancer) (b) Log2 fold changes (relative to
pDNA) in CRISPR screen for sgRNAs targeting Peak 2319. FDR values were calculated using the Benjamini-Hochberg method. c Schematic of p53
motifs and sgRNA targets located in Peak 384. (ChromHMM track legend: yellow = weak/poised enhancer) (d) Log2 fold changes (relative to
pDNA) in CRISPR screen for sgRNAs targeting Peak 384. FDR values were calculated using the Benjamini-Hochberg method. e Comparison of
cellular growth rates following inhibition of Peak 2319 or Peak 384. P-values were calculated using the two-tailed unpaired Student’s t-test with
equal variances. **P < 0.01, *P < 0.05
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gene (Fig. 3c). Peak 384 contains three p53 motifs, two
of which were targeted by sgRNAs in our peak-targeting
CRISPR library (Fig. 3c). We identified multiple sgRNAs
targeting the first of those motifs that were significantly
depleted in our peak-targeting CRISPRi screen (Fig. 3d).
We hypothesized that the p53 binding sites within Peak
384 are components of a regulatory element located
deep within an intergenic region of the genome and
selected sgRNAs targeting this peak for experimental
validation.
To experimentally validate that selected p53 binding
sites represent functional regulatory elements we evaluated the impact of repressing each individual binding
site on cell proliferation. We used lentivirus to stably
transduce individual sgRNAs targeting the p53 binding
sites of interest into dCas9-KRAB-expressing 769P cells.
In addition, we generated stable dCas9-KRAB-expressing
cell lines harboring an sgRNA targeting RAD51C, an
sgRNA targeting an intergenic region of the genome, or
an sgRNA with no genomic target. The resulting 7 cell
lines were cultured in parallel for 18 days and population
doublings were evaluated at each passage. Cell lines harboring sgRNAs targeting RAD51C, Peak 2319, and Peak
384 underwent significantly fewer population doublings
as compared to cell lines containing negative control
sgRNAs (Fig. 3e). Furthermore, we observed a significant
difference in population doublings between cells harboring the sgRNA targeting the RAD51C TSS (RAD51C)
and cells containing an sgRNA targeting the p53 binding
site within the first intron of RAD51C (2319.1–1) (Fig.
3e). This observation suggests that sgRNAs targeting the
RAD51C TSS and the RAD51C intron influence cell
proliferation through distinct mechanisms (direct transcriptional interference of RAD51C and inhibition of
regulatory element activity, respectively). We detected a
similar impact on cell proliferation for two different
sgRNAs targeting Peak 2319 in our validation experiments despite their differing degrees of depletion in our
CRISPRi screen (Fig. 3b, e). This observation suggests
that many of the modest proliferation phenotypes generated by sgRNAs in our CRISPRi screen may translate to
more potent impacts on cell proliferation in focused
validation experiments. Altogether, our results confirm
that pooled CRISPR screens can be used to identify
functional regulatory elements that influence cell
proliferation.
In addition to the sgRNAs that were significantly depleted in our CRISPRi screen we identified several
sgRNAs that were significantly enriched. For example,
multiple sgRNAs targeting Peak 1267 resulted in a significant proliferative advantage in our CRISPRi screen
(Fig. 2h). Peak 1267 contains five p53 motifs, two of
which were targeted by sgRNAs in our peak-targeting
CRISPR library (Additional file 3: Figure S3A). Although
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Peak 1267 is located within the first intron of
TNFRSF10A, knockout of TNFRSF10A had no impact
on cell proliferation in our gene-targeting CRISPRko
screen (Additional file 3: Figure S3A, Figure S3B). In
contrast, we identified multiple sgRNAs targeting the
second p53 consensus motif in Peak 1267 that were significantly enriched in our peak-targeting CRISPRi screen
(Additional file 3: Figure S3C). Importantly, these results
demonstrate that regulatory elements can be functionally
dissociated from proximal protein-coding genes.
Pooled CRISPR screen identifies p53-bound regulatory
elements that influence the DNA damage response

To evaluate the ability of a pooled CRISPR screen to
identify regulatory elements that influence additional
biological processes we next investigated the p53mediated response to DNA damage. First, we utilized
our gene-targeting CRISPR library to ensure that a
CRISPR screen would be able to identify protein-coding
genes that are required for cell cycle arrest in response
to DNA damage. We infected Cas9-expressing 769P
cells with our gene-targeting library at an MOI of ~ 0.5
and a representation of 1000 cells per sgRNA. Libraryinfected cells were cultured in the presence of the DNA
damage-inducing agent doxorubicin for 21 days, genomic DNA was isolated, and targeted sequencing was
performed to evaluate changes in sgRNA abundance
relative to the CRISPR library pDNA (Additional file 8:
Table S3). Analysis with MAGeCK revealed a strong
correlation in sgRNA enrichment/depletion across biological replicates indicating that our screening results
are highly reproducible (Fig. 4a, Additional file 18: Table
S13). We identified several sgRNAs that prevented cell
cycle arrest in response to DNA damage. (Fig. 4a,
Additional file 18: Table S13). Among the most enriched
sgRNAs were those targeting p53, CDKN1A, and
SLC30A1 (Fig. 4b, Fig. 4c, Additional file 19: Table S14).
These data demonstrate that a CRISPR screen can be
used to identify genes that are required for cell cycle
arrest in response to DNA damage.
We next used our peak-targeting CRISPRi library to
search for regulatory elements involved in the p53mediated response to DNA damage. We infected dCas9KRAB-expressing 769P cells with our peak-targeting
library at an MOI of ~ 0.5 and a representation of 1000
cells per sgRNA. Library-infected cells were cultured in
the presence of doxorubicin for 21 days, genomic DNA
was isolated, and targeted sequencing was performed to
evaluate changes in sgRNA abundance relative to the
CRISPR library pDNA (Additional file 12: Table S7).
Analysis with MAGeCK revealed a relatively weak correlation in sgRNA enrichment/depletion across biological replicates (Fig. 4d). This weak correlation likely
results from the combination of reduced proliferation in
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Fig. 4 p53-bound regulatory elements influence cellular response to DNA damage. a Comparison of log2 fold changes (relative to pDNA) for all
sgRNAs in gene-targeting CRISPR library between replicates. b Log2 fold changes (relative to pDNA) in CRISPR screen for sgRNAs targeting
selected subset of genes. FDR values were calculated using the Benjamini-Hochberg method. c Visualization of enrichment/depletion for sgRNAs
targeting a selected subset of genes (red) compared to all sgRNAs in CRISPR library (black). d Comparison of log2 fold changes (relative to pDNA)
for all sgRNAs in peak-targeting CRISPR library between replicates. e Volcano plot comparing significance of sgRNA enrichment/depletion and
log2 fold change (relative to pDNA) for all sgRNAs in CRISPR library. f Visualization of enrichment/depletion for sgRNAs targeting a selected subset
of peaks (red) compared to all sgRNAs in CRISPR library (black). g Comparison of log2 fold change (relative to pDNA) and distance from nearest
annotated TSS for all sgRNAs in CRISPR library

cells treated with doxorubicin and the less potent enrichments/depletions observed in screens performed
with our peak-targeting CRISPR library. Despite weak
overall correlation in sgRNA enrichment/depletion
across replicates we were able to identify several sgRNAs
that were significantly enriched in our screen (Fig. 4e,
Additional file 20: Table S15). Interestingly, the three
peaks that had the most significant impact on cycle arrest in response to DNA damage (Peak 974, Peak 975,

and Peak 976) are located within a 15 kb window surrounding the CDKN1A transcription start site. Aside
from p53, CDKN1A was the most enriched gene in our
DNA damage screen performed with the gene-targeting
CRISPR library (Fig. 4b, c, f, Additional file 21: Table
S16). Although most of the p53 binding sites identified
in our screen were located within 10 kb of an annotated
TSS, at least one was located more than 250 kb away
from the nearest TSS (Fig. 4g). Altogether, these data
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provide an additional example of a pooled CRISPR
screen being used to successfully identify functional
regulatory elements.
We again tested the ability of CRISPRko technology to
identify functional regulatory elements by performing a
DNA damage response screen in cells expressing Cas9
as opposed to dCas9-KRAB. We infected Cas9expressing 769P cells with our peak-targeting library at
an MOI of ~ 0.5 and a representation of 1000 cells per
sgRNA. Library-infected cells were cultured in the presence of doxorubicin for 21 days, genomic DNA was
isolated, and targeted sequencing was performed to
evaluate changes in sgRNA abundance relative to the
CRISPR library pDNA (Additional file 15: Table S10).
Analysis with MAGeCK revealed a moderate correlation
in sgRNA enrichment/depletion across biological replicates (Additional file 4: Figure S4A, Additional file 22:
Table S17). While we did identify p53 binding sites in
which CRISPR-mediated knockout prevented cell cycle
arrest in response to DNA damage, the magnitude of
sgRNA enrichment was less significant as compared to
the CRISPRi screen (Additional file 4: Figure S4B,
Additional file 23: Table S18). Moreover, the sgRNA enrichments were far less pronounced than we observed in
the CRISPRi screen (Additional file 4: Figure S4C, Figure
S4D). Once again, we observed minimal overlap in the
sgRNAs that were significantly enriched/depleted across
the CRISPRko and CRISPRi screens of the DNA damage
response (Additional file 4: Figure S4E). Furthermore,
none of the p53 binding sites that appeared to impact
the DNA damage response in the CRISPRko were
located near genes that were significantly enriched/depleted in our gene-targeting CRISPR screen. Based on
these data we focused our validation efforts on p53 binding sites identified in our CRISPRi screen.
Repression of p53-bound regulatory elements prevents
cell cycle arrest in response to DNA damage

Among the sgRNAs that were most enriched in our
peak-targeting CRISPRi screen of the DNA damage response were those targeting ChIP-Seq peaks nearest
CDKN1A (Fig. 4f). More specifically, Peak 975 overlaps
the CDKN1A TSS, Peak 974 is located 10 kb upstream
of the CDKN1A TSS, and Peak 976 is located 5 kb
downstream of the CDKN1A TSS (Fig. 5a). Peak 975
contains three p53 consensus motifs and multiple
sgRNAs targeting the first of those motifs were significantly enriched in our CRISPRi screen (Fig. 5b). Peak
976 contains eight p53 consensus motifs and we identified sgRNAs targeting several of those motifs that were
significantly enriched in our CRISPRi screen (Fig. 5c).
Lastly, Peak 974 contains four p53 consensus motifs and
sgRNAs targeting each of those motifs were significantly
enriched in our CRISPRi screen, although the magnitude
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of enrichment was not as pronounced as with sgRNAs
targeting Peak 975 and Peak 976 (Fig. 5d). We hypothesized that the p53 binding sites located within these
ChIP-Seq peaks are components of regulatory elements
that modulate CDKN1A expression and selected an
sgRNA targeting Peak 975 for experimental validation.
Also among the most enriched sgRNAs in our peaktargeting CRISPRi screen of the DNA damage response
was one targeting Peak 685 (Fig. 4e). Peak 685 is located
more than 250 kb away from the nearest annotated
protein-coding gene and contains two p53 motifs, both
of which were targeted by sgRNAs in our peak-targeting
CRISPR library (Fig. 5e). We identified one sgRNA targeting the second of those motifs that was significantly
enriched in our peak-targeting CRISPRi screen (Fig. 5f).
We hypothesized that this p53 binding site is a component of a regulatory element located deep within an
intergenic region of the genome and selected an sgRNA
targeting Peak 685 for experimental validation.
To experimentally validate that the selected p53 binding sites represent functional regulatory elements we
evaluated the impact of repressing individual binding
sites on cell cycle arrest in response to DNA damage.
We used lentivirus to stably transduce individual
sgRNAs targeting p53 binding sites of interest into
dCas9-KRAB-expressing 769P cells. In addition, we generated stable dCas9-KRAB-expressing cell lines harboring an sgRNA targeting p53, an sgRNA targeting an
intergenic region of the genome, or an sgRNA with no
genomic target. The resulting 5 cell lines were cultured
in the presence or absence of doxorubicin for 16 h
followed by cell cycle analysis (Additional file 5: Figure
S5). All of the stable cell lines we generated displayed
similar cell cycle profiles in standard culture conditions,
with 12–15% of total cells in S-phase (Fig. 5g). In response to doxorubicin treatment cell lines harboring
negative control sgRNAs dropped to 0.5% of total cells
in S-phase (Fig. 5g). In contrast, 10% of cells harboring
sgRNAs targeting p53 remained in S-phase after treatment with doxorubicin (Fig. 5g). Likewise, cells containing sgRNAs targeting Peak 975 and Peak 685 exhibited
significantly lower levels of cell cycle arrest with 4.27
and 3.72% of total cells in S-phase, respectively (Fig. 5g).
Altogether, these results confirm that pooled CRISPR
screens can be used to identify functional regulatory
elements that influence the DNA damage response.
Moreover, these data further demonstrate that pooled
CRISPR screening can be used as a general approach to
identify functional regulatory elements that influence
diverse biological processes.

Discussion
In recent years CRISPR-based approaches have emerged
as powerful tools for functional genomics studies. Pooled
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Fig. 5 Functional characterization of p53-bound regulatory elements that influence cellular response to DNA damage. a Schematic of p53 motifs
and sgRNA targets located in Peaks 974, 975, and 976. (ChromHMM track legend: red = active promoter; orange = strong enhancer; yellow =
weak/poised enhancer; dark green = transcriptional transition/elongation; light green = weak transcribed) (b-d) Log2 fold changes (relative to
pDNA) in CRISPR screen for sgRNAs targeting b Peak 975, c Peak 976, and d Peak 974. FDR values were calculated using the Benjamini-Hochberg
method. e Schematic of p53 motifs and sgRNA targets located in Peak 685. f Log2 fold changes (relative to pDNA) in CRISPR screen for sgRNAs
targeting Peak 685. FDR values were calculated using the Benjamini-Hochberg method. g Cell cycle analysis of DNA damage response following
inhibition of Peak 975 or Peak 685. P-values were calculated using the two-tailed unpaired Student’s t-test with equal variances. **P < 0.01

CRISPR screens in particular have been widely used to
identify protein-coding genes involved in a variety of cellular pathways and processes [5–8]. Here, we explore
the application of pooled CRISPR screening in the functional characterization of regulatory elements throughout the genome. We developed a cell-based screening
system to profile the functional role of p53-bound regulatory elements in multiple biological contexts. Using
this system we identified several regulatory elements that
influence cell proliferation and/or cell cycle arrest in response to DNA damage. Moreover, the functional significance for several of the regulatory elements we
uncovered was confirmed using orthogonal experimental
approaches.
The regulatory elements identified in our screens
varied greatly in their proximity to the genes in which
they regulate. Among the most conventional regulatory elements we identified were those within Peak
2319 and Peak 975. These peaks are both located
within 1 kb of a transcription start site (RAD51C and
CDKN1A, respectively) and their inhibition phenocopied the effect of gene knockout. Surprisingly, some of
the regulatory elements identified in our screens were
in close proximity to transcription start sites but were
not functionally associated with nearby genes. For example, inhibition of Peak 1267 had a significant impact on both cell proliferation and cell cycle arrest in
response to DNA damage. Although Peak 1267 is located within 1 kb of the TNFRSF10A transcription
start site, knockout of TNFRSF10A had no effect on
either process. Despite its proximity to TNFRSF10A,
Peak 1267 likely functions as a distal regulatory element for other genes involved in cell proliferation and/
or the DNA damage response.
Several of the regulatory elements we discovered are
located in intergenic regions of the genome that are devoid of any prior functional annotation. For example,
Peak 384 is located more than 200 kb away from the
nearest annotated gene yet inhibition of this site resulted in a significant reduction in cell proliferation.
Among the p53 binding sites that had the greatest impact on cell cycle arrest in response to DNA damage
was Peak 685. Interestingly, this peak is located more
than 250 kb from the nearest annotated gene. These examples highlight the ability of pooled CRISPR screens

to identify functional regulatory elements located deep
within intergenic regions the human genome. While we
hypothesize that the activity of these intergenic regulatory elements is p53-dependent, we cannot exclude the
possibility that they influence cell proliferation and/or
cell cycle arrest through a p53-independent mechanism.
Regardless, identifying the gene targets of these noncoding regulatory elements will be an exciting area of
future research.
In the course of our study we evaluated multiple
methods for perturbing the function of regulatory elements. More specifically, we performed CRISPRi screens
with cells expressing dCas9-KRAB as well as CRISPRko
screens with cells expressing Cas9. While pooled
CRISPR screens have been performed using dCas9 in
the absence of a KRAB domain fusion, we reasoned that
the repressive properties of dCas9-KRAB would result in
greater impacts on regulatory element function and, in
turn, more pronounced cellular phenotypes in our
screens. Both CRISPRi and CRISPRko screening
methods resulted in the enrichment/depletion of
sgRNAs targeting p53 binding sites, although we observed minimal overlap between the different approaches. We identified only one p53 binding site (Peak
1267) targeted by sgRNAs that were enriched using both
technologies. Importantly, the sgRNA enrichments/depletions we observed in our peak-targeting CRISPRi
screens more closely reflected the results of our genetargeting CRISPRko screens. We hypothesize that the
degenerate nature of the p53 consensus motif allows p53
binding sites to be tolerant of indels that result from
DNA cleavage by Cas9 and prevents CRISPRko-based
approaches from effectively perturbing their function.
Given that many transcription factors bind to degenerate
sequence motifs we recommend the use of CRISPRibased methods when performing pooled CRISPR screens
focused on the identification of functional regulatory elements. In contrast, CRISPRko-based approaches that
introduce indels would be more appropriate for screens
intended to functionally profile the sequences of known
regulatory elements at high resolution. Likewise, CRISPR
screens performed using dCas9 (without a KRAB domain fusion) could interfere with transcription factor
binding and distinguish sites within a regulatory element
that are required for activity.
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With regards to our CRISPR library design, we chose
to target all PAM-containing sequences that were proximal to p53 consensus motifs within p53 binding sites
when constructing our peak-targeting CRISPR library.
While sgRNA design principles have been described for
both CRISPRi and CRISPRko approaches, the methods
for generating these rules have been based exclusively
on the perturbation of protein-coding gene function [14,
35, 36]. Consequently, many of the features that are incorporated into these design rules (e.g. location within
coding sequence, distance to TSS) are not applicable to
the design of sgRNAs targeting regulatory elements. The
inclusion of all possible sgRNAs in our peak-targeting
CRISPR library did result in more variability between
sgRNAs with common targets than is typically observed
in gene-targeting CRISPR screens performed with optimized sgRNA libraries. However, our comprehensive library design was essential for the identification of
functional regulatory elements in this study. Some of the
p53 motifs profiled in our screens could only be targeted
by one sgRNA, which raises the concern that the resulting phenotypes might be caused by off-target effects.
However, many of those motifs occurred within p53
ChIP-Seq peaks that harbored multiple p53 motifs and
were targeted by several additional sgRNAs. Future efforts to characterize sgRNA design rules when targeting
regulatory elements will aid in distinguishing active from
inactive sgRNAs, reduce the potential for off-target effects, and lead to increased reproducibility across
candidate sgRNAs with common targets. Moreover, optimized sgRNA design principles would reduce the number of sgRNAs required to effectively screen regulatory
elements and ultimately increase the number of genomic
regions that can be profiled in a pooled CRISPR screen.
In this study we developed screening systems to
identify p53-bound regulatory elements that influence
cell proliferation and/or cell cycle arrest in response
to DNA damage. However, the approaches we describe here can be adapted to profile the function of
regulatory elements bound by any transcription factor.
Alternatively, these methods can be utilized to interrogate the function of intergenic regions of interest
identified in genome-wide association studies (GWAS)
or noncoding regions that have been shown to harbor
rare genetic variants identified in patient samples.
One major challenge associated with each of the
aforementioned applications is the development of
relevant cell-based model systems in which to perform pooled CRISPR screens.

Conclusions
In conclusion, our findings demonstrate that CRISPRbased screening methods can be used to characterize the

Page 12 of 15

functional role of noncoding regulatory elements in diverse biological processes. Moreover, our results provide
valuable insight into practical considerations for the design and implementation of CRISPR screens focused on
noncoding regions of the genome.

Methods
Cell culture

Human renal adenocarcinoma cells (769P, ATCC CRL1933) were cultured in RPMI medium supplemented
with 10% Fetal Bovine Serum (Sigma-Aldrich). Cells
were cultured with 250 nM doxorubicin (Sigma) for
pooled CRISPR screens and validation experiments to
induce DNA damage. Cells were tested periodically for
mycoplasma contamination and were authenticated by
SNP fingerprinting at both the initiation and completion
of each CRISPR screen.
Generation of Cas9-expressing cell lines

Lentivirus was produced from vectors encoding Cas9
(Addgene, 96924) and dCas9-KRAB (Addgene, 96918) as
previously described [14]. For infection, 1.5e6 cells were
plated in a 12-well tissue culture dish along with 2 mL
media, 700 μL lentivirus, and 1 mg/mL polybrene per
well. Plates were then centrifuged at 930 xg for 2 h at
30 °C. Following centrifugation 2 mL of fresh media was
added dropwise to each well and cells were incubated
overnight at 37 °C. Cells were collected 24 h postinfection and transferred into flasks with fresh media
supplemented with 4 μg/mL blasticidin. Cells were cultured in the presence of blasticidin throughout expansion and Cas9 expression was confirmed by western
blot.
Western blot

Cell pellets were lysed and protein concentrations were
quantified by BCA assay (ThermoFisher). Western blots
were performed on protein lysates (60 μg/well). Primary
antibodies used were anti-Cas9 (Cell Signaling Technology, 14697) and anti-H3 (Cell Signaling Technology,
14269). Protein was visualized using an IRDye800CWconjugated secondary antibody (Licor, 926–32210).
Gene-targeting CRISPR library design and construction

The gene-targeting CRISPR library was designed
against 330 protein-coding genes that are predicted targets of p53 [29]. The library was comprised of 4
sgRNAs against each p53 target gene as well as 4
sgRNAs against p53. As controls, 70 sgRNAs targeting
intergenic sites and 70 sgRNAs with no genomic target
were included in the library. All sgRNA sequences are
listed in Additional file 7: Table S2. Library cloning into
lentiGuide-Puro (Addgene, 52963) and large-scale virus
production was performed as previously described [14].
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Peak-targeting CRISPR library design and construction

The peak-targeting CRISPR library was designed against
2036 previously characterized p53 ChIP-Seq peaks [29].
The library was comprised of sgRNAs targeting all possible PAM-containing sites located within 16 bp of a p53
consensus motif (CWWG [N]2-12CWWG). All sgRNAs
with putative off-target sites within protein-coding genes
were excluded from the library. In addition, sgRNAs with
more than one potential off-target site within unrelated
noncoding regions of the genome were excluded. Cutting
frequency determination (CFD) was used to evaluate offtarget potential with a CFD = 1 being considered a potential off-target site [36]. As controls, 500 sgRNAs targeting
intergenic sites and 500 sgRNAs with no genomic target
were included in the library. All sgRNA sequences are
listed in Additional file 11: Table S6. Library cloning into
lentiGuide-Puro (Addgene, 52963) and large-scale virus
production was performed as previously described [14].
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calculated relative to their abundance in the initial plasmid DNA library.
Generation of stable CRISPRi cell lines

Individual sgRNAs were cloned into lentiGuide-Puro
(Addgene, 52963) and lentivirus was generated as previously described [14]. For infection, 1.5e6 dCas9-KRABexpressing cells were plated in a 12-well tissue culture
dish along with 2 mL media, 150 μL lentivirus, and 1
mg/mL polybrene per well. Plates were then centrifuged
at 930 xg for 2 h at 30 °C. Following centrifugation 2 mL
of fresh media was added dropwise to each well and cells
were incubated overnight at 37 °C. Cells were collected
24 h post-infection and transferred into flasks with fresh
media supplemented with 4 μg/mL blasticidin and 6 μg/
mL puromycin. Cells were cultured in the presence of
blasticidin and puromycin throughout expansion. The
sgRNA sequences used to generate each cell line are
listed in Additional file 24: Table S19.

Pooled CRISPR screens

The lentiviral titer for each pooled CRISPR library was determined as previously described [14]. Library transductions
were performed with an estimated transduction efficiency
of 30–50% using sufficient cell numbers such that 1000
cells/sgRNA remained after puromycin selection. Cells
were cultured in the presence of puromycin (6 μg/mL) for
7 days post-infection to ensure complete selection. At each
passage adequate cell numbers were re-seeded to maintain
a library representation of 1000 cells/sgRNA. At the completion of each screen cell pellets were collected, washed
with PBS, and frozen at − 20 °C prior to gDNA isolation.
All screens were performed in biological triplicate.
Targeted sequencing libraries

Genomic DNA was isolated using NucleoSpin Blood XL,
Blood L, and Blood columns according to the manufacturer’s protocol (Machery Nagel). Targeted sequencing
libraries were generated directly from genomic DNA as
previously described [14]. Libraries were size-selected
using Agencourt AMPure XP beads (Beckman Coulter).
Purified libraries were sequenced on a HiSeq 2500
(Illumina).
Pooled CRISPR screen analysis

Sequencing reads were translated into read counts by
extracting the 20 nt sgRNA sequence from each read
followed by alignment to the library reference. For each
screen we achieved an average sequencing depth of >
500 aligned reads per sgRNA per replicate. Enrichment/
depletion of sgRNAs in each screen was determined with
MAGeCK using the alphamedian option to calculate fold
changes [34]. Fold changes in sgRNA abundances were

Cell proliferation analysis

Stable CRISPRi cell lines harboring individual sgRNAs
were seeded at equal cell numbers and cultured in parallel for 18 days. Every 2–3 days cells were collected,
counted, and re-seeded at equal cell numbers. All experiments were performed in triplicate.
Cell cycle analysis

Stable CRISPRi cell lines harboring individual sgRNAs
were seeded at equal cell numbers and cultured in the
presence or absence of doxorubicin. Cell cycle analysis
was performed using the 488 EdU Click Proliferation Kit
(BD Biosciences, 565455) in conjunction with propidium
iodide staining as per the manufacturer’s guidelines. All
experiments were performed in triplicate.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12864-020-6497-0.
Additional file 1: Figure S1. p53 enrichment in pooled CRISPR screens
requires wildtype p53. p53 enrichment scores (categorized by p53
mutation status) from pooled CRISPR knockout screens in 350 cancer cell
lines. P-values were calculated using the two-tailed unpaired Student’s ttest with equal variances. ***P < 0.001, **P < 0.01.
Additional file 2: Figure S2. CRISPR-knockout screen identifies p53bound regulatory elements that influence cell proliferation. (A) Comparison of log2 fold changes (relative to pDNA) for all sgRNAs between replicates in 769P-Cas9 cells. (B) Volcano plot comparing significance of
sgRNA enrichment/depletion and log2 fold change (relative to pDNA) in
769P-Cas9 cells for all sgRNAs in CRISPR library. (C) Visualization of enrichment/depletion in 769P-Cas9 cells for sgRNAs targeting a selected subset
of peaks (red) compared to all sgRNAs in CRISPR library (black). (D) Comparison of log2 fold change (relative to pDNA) and distance from nearest
annotated TSS for all sgRNAs in CRISPR library. (E) Comparison of log2
fold changes (relative to pDNA) for all sgRNAs between 769P-Cas9 and
769P-dCas9-KRAB screens.
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Additional file 3: Figure S3. CRISPR screens uncover functional
dissociation of p53-bound regulatory element and proximal proteincoding gene. (A) Schematic of p53 motifs and sgRNA targets located in
Peak 1267. (ChromHMM track legend: red = active promoter) (B) Log2 fold
changes (relative to pDNA) in CRISPR screen for sgRNAs targeting
TNFRSF10A in 769P-Cas9 cells. (C) Log2 fold changes (relative to pDNA) in
CRISPR screen for sgRNAs targeting Peak 1267 in 769P-dCas9-KRAB cells.
FDR values were calculated using the Benjamini-Hochberg method.
Additional file 4: Figure S4. CRISPR-knockout screen identifies p53bound regulatory elements that influence cellular response to DNA damage. (A) Comparison of log2 fold changes (relative to pDNA) for all
sgRNAs between replicates in 769P-Cas9 cells. (B) Volcano plot comparing significance of sgRNA enrichment/depletion and log2 fold change
(relative to pDNA) in 769P-Cas9 cells for all sgRNAs in CRISPR library. (C)
Visualization of enrichment/depletion in 769P-Cas9 cells for sgRNAs targeting a selected subset of peaks (red) compared to all sgRNAs in CRISPR
library (black). (D) Comparison of log2 fold change (relative to pDNA) and
distance from nearest annotated TSS for all sgRNAs in CRISPR library. (E)
Comparison of log2 fold changes (relative to pDNA) for all sgRNAs between 769P-Cas9 and 769P-dCas9-KRAB screens.
Additional file 5: Figure S5. p53 inhibition influences cellular response to
DNA damage. Raw flow cytometry data from cell cycle analysis experiments.
Additional file 6: Table S1. Project Achilles – p53 status and
enrichment data.
Additional file 7: Table S2. CRISPR library targeting p53-regulated
protein-coding genes.
Additional file 8: Table S3. CRISPR screen raw read counts (Gene
Library/Cas9).
Additional file 9: Table S4. Guide-level MAGeCK output (Gene Library/
Cas9/Untreated).
Additional file 10: Table S5. Gene-level MAGeCK output (Gene Library/
Cas9/Untreated).
Additional file 11: Table S6. CRISPR library targeting p53 binding sites.
Additional file 12: Table S7. CRISPR screen raw read counts (Peak
Library/dCas9-KRAB).
Additional file 13: Table S8. Guide-level MAGeCK output (Peak Library/
dCas9-KRAB/Untreated).
Additional file 14: Table S9. Peak-level MAGeCK output (Peak Library/
dCas9-KRAB/Untreated).
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CRISPRko: CRISPR knockout; MAGeCK: Model-based analysis of genome-wide
CRISPR-Cas9 knockout; MOI: Multiplicity of infection; sgRNA: single guide
RNA; TSS: Transcription start site
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